You searched for
Tag:
Corporate
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
23/06/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
2022 for Chiesi: The Group’s international growth continues
05/04/2023
Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
24/02/2023
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
22/02/2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27/01/2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17/01/2023
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
21/11/2022
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
05/09/2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27/07/2022
Chiesi tracks actions taken for a healthier, more sustainable future
14/07/2022
Chiesi Group continues to grow
31/03/2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16/12/2021